Clinical trial
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With…
NCT00499291 · Eastern Cooperative Oncology Group, Other · Withdrawn
Key facts
| NCT number | NCT00499291 |
|---|---|
| Title | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors |
| Official title | Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug, Procedure |
| Interventions | paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis, pharmacological study, polymerase chain reaction |
| Enrollment | 0 |
| Start date | Sep 1, 2006 |
| First posted | Jul 11, 2007 |
| Last update posted | May 25, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: